$BRKR earnings report

Q3-26 revenue of $874.0 million, up 1.6% yoy; non-GAAP operating margin of 16.3%, up 400 bps yoy; non-GAAP diluted EPS of $0.56, up 24.4% yoy. AlphAI read Bruker's Q3-26 filing as mixed. 2 quarters are on record below.

Q3-26

AlphAI · Earnings readBRKR · Q3-26 · ended September 30, 2026

Q3-26 revenue of $874.0 million, up 1.6% yoy; non-GAAP operating margin of 16.3%, up 400 bps yoy; non-GAAP diluted EPS of $0.56, up 24.4% yoy

→Mixed quarter

Revenue growth was 1.6% and organic revenue growth was 0.7%, while BSI organic revenue declined 0.4%. Non-GAAP operating margin expanded to 16.3% and non-GAAP diluted EPS increased 24.4%, but GAAP results included a $174.5 million non-cash goodwill impairment charge and a GAAP operating loss of $(91.0) million.

Revenue
$874M
1.6% y/y
Bruker BIOS
$397M
FY26 outlook
$3.52 to $3.56 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3-26 total revenueGAAP$874M–1.6%
Q3-26 organic revenuenon-GAAP$866.2M–0.7%
Q3-26 CER currency revenuenon-GAAP$881.2M–2.4%
Q3-26 gross profitGAAP$429.3M––
Q3-26 gross profit marginGAAP49.1%––
Q3-26 gross profitnon-GAAP$448.3M––
Q3-26 gross profit marginnon-GAAP51.3%––
Q3-26 selling, general and administrative expensesGAAP$226.5M––
Q3-26 research and development expensesGAAP$92M––
Q3-26 total operating expensesGAAP$520.3M––
Q3-26 operating lossGAAP−$91M––
Q3-26 operating loss marginGAAP(10.4)%––
Q3-26 operating incomenon-GAAP$142.6M––
Q3-26 operating income marginnon-GAAP16.3%–up 400 bps yoy
Q3-26 net loss attributable to Bruker Corporation common shareholdersGAAP−$122.8M––
Q3-26 net income attributable to Bruker Corporation common shareholdersnon-GAAP$86.3M––
Q3-26 diluted loss per common share attributable to Bruker Corporation common shareholdersGAAP$(0.81)––
Q3-26 diluted net income per common share attributable to Bruker Corporation common shareholdersnon-GAAP$0.56–24.4%
Q3-26 net cash provided by operating activitiesGAAP$118.2M––
Q3-26 free cash flownon-GAAP$96.7M––
First nine months of 2026 total revenueGAAP$2.54B–3.1%
First nine months of 2026 organic revenuenon-GAAP$2.45B–(0.3)%
First nine months of 2026 gross profitGAAP$1.23B––
First nine months of 2026 gross profit marginGAAP48.3%––
First nine months of 2026 operating lossGAAP−$146.1M––
First nine months of 2026 operating incomenon-GAAP$345.3M––
First nine months of 2026 operating income marginnon-GAAP13.6%––
First nine months of 2026 net loss attributable to Bruker Corporation common shareholdersGAAP−$182.2M––
First nine months of 2026 net income attributable to Bruker Corporation common shareholdersnon-GAAP$208.7M––
First nine months of 2026 diluted loss per common share attributable to Bruker Corporation common shareholdersGAAP$(1.20)––
First nine months of 2026 diluted net income per common share attributable to Bruker Corporation common shareholdersnon-GAAP$1.36––
First nine months of 2026 net cash provided by operating activitiesGAAP$112M––
First nine months of 2026 free cash flownon-GAAP$37.5M––

Segments

SegmentRevenueq/qy/y
Bruker BIOSNot stated$397.2M––
Bruker MIDNot stated$133.6M––
Bruker NanoNot stated$263.1M––
BSI Revenue TotalOrganic revenue decreased by 0.4% yoy.$793.9M–0.8%
BESTOrganic revenue increased 11.8%, net of intercompany eliminations.$82.1M–11.2%

FY26 outlook

  • Revenue$3.52 to $3.56 billion
  • NoteFY25 revenues of $3.44 billion
  • Note2.5% to 3.5% year-over-year reported revenue growth
  • NoteOrganic revenue growth of 1% to 2%
  • NoteM&A revenue growth of approximately 1.5%
  • NoteCER revenue growth of 2.5% to 3.5%
  • NoteForeign currency neutral to revenue (previously a tailwind of 0.5%)
  • NoteFY26 non-GAAP EPS of $2.10 to $2.15 compared to $1.83 in FY25
  • Note15% to 17% year-over-year increase in FY26 non-GAAP EPS

Capital returns

  • Payment of dividends to shareholders of $(18.7) million in the three months ended September 30, 2026.
  • Payment of dividends to shareholders of $(55.8) million in the nine months ended September 30, 2026.

What drove it

  • Q3-26 acquisitions contributed 1.7% to revenue growth.
  • Foreign currency translation had an unfavorable impact of -0.8% yoy on Q3-26 revenue.
  • Q3-26 BEST organic revenue increased 11.8%, net of intercompany eliminations.
  • Management cited cost discipline and execution as drivers of margin expansion and non-GAAP EPS growth.
  • Management said BSI book-to-bill was greater than one for the fifth consecutive quarter.
  • Management said BSI organic bookings and backlog were both up mid-single digits % year-to-date.

Concerns

  • Q3-26 BSI organic revenue decreased by 0.4% yoy.
  • First nine months of 2026 organic revenue decreased by 0.3% yoy, and BSI organic revenue decreased by 1.0%.
  • Q3-26 GAAP operating loss was $(91.0) million and included $174.5 million of non-cash goodwill impairment charges.
  • First nine months of 2026 GAAP operating loss was $(146.1) million, compared to $(8.1) million in the first nine months of 2025.
  • Foreign currency translation was expected to be neutral to FY26 revenue, updated from a previously expected tailwind of 0.5%.

What to watch

  • Progress toward FY26 organic revenue growth of 1% to 2%.
  • Whether BSI booking and backlog trends translate into the revenue growth acceleration management expects.
  • Sustainability of non-GAAP operating margin expansion after Q3-26 margin reached 16.3%.
  • Foreign currency effects, which reduced Q3-26 reported revenue growth by -0.8% yoy.
  • The impact of the goodwill impairment charges on GAAP profitability.

Balance sheet and cash flow

  • Cash and cash equivalents were $119.7 million as of September 30, 2026, compared to $298.8 million as of December 31, 2025.
  • Long-term debt was $1,703.0 million as of September 30, 2026, compared to $1,852.5 million as of December 31, 2025.
  • Current portion of long-term debt and finance lease obligations was $10.4 million as of September 30, 2026, compared to $16.6 million as of December 31, 2025.
  • Purchases of property, plant and equipment and intangible assets were $(21.5) million in Q3-26 and $(74.5) million in the first nine months of 2026.
  • Cash paid for acquisitions, net of cash acquired, was $(57.0) million in Q3-26 and $(73.0) million in the first nine months of 2026.
  • Repayment of long-term debt was $(2.7) million in Q3-26 and $(186.3) million in the first nine months of 2026.

Analysis

Bruker reported Q3-26 revenue of $874.0 million, up 1.6% yoy, with organic revenue growth of 0.7%. Acquisitions contributed 1.7% to growth, while foreign currency translation reduced revenue by -0.8% yoy. The first nine months showed $2,535.9 million of revenue, up 3.1%, but organic revenue decreased by 0.3%, highlighting the limited underlying growth across the year to date.

Segment performance was uneven. BSI revenue was $793.9 million, up 0.8% yoy, but BSI organic revenue decreased by 0.4%. BEST generated $82.1 million of revenue, up 11.2% yoy, with 11.8% organic growth net of intercompany eliminations. Management pointed to a fifth consecutive quarter of BSI book-to-bill greater than one, strengthening demand in most end markets and BSI organic bookings and backlog both up mid-single digits % year-to-date.

Profitability improved materially on a non-GAAP basis. Q3-26 non-GAAP operating income increased to $142.6 million from $105.9 million, and non-GAAP operating margin expanded to 16.3% from 12.3%. Non-GAAP diluted EPS rose to $0.56 from $0.45. GAAP results remained sharply negative, however, as Q3-26 included $174.5 million of non-cash goodwill impairment charges, producing a GAAP operating loss of $(91.0) million and GAAP diluted loss per share of $(0.81).

Cash flow improved versus the prior-year period. Q3-26 net cash provided by operating activities was $118.2 million and free cash flow was $96.7 million, compared with $(33.2) million and $(54.1) million, respectively, a year earlier. Cash and cash equivalents were $119.7 million at September 30, 2026, while long-term debt was $1,703.0 million. The company paid $(18.7) million of shareholder dividends in Q3-26 and $(55.8) million in the first nine months.

Bruker reconfirmed FY26 organic revenue growth and non-GAAP EPS guidance while updating currency assumptions. It expects FY26 revenue of $3.52 to $3.56 billion, including 1% to 2% organic growth, and FY26 non-GAAP EPS of $2.10 to $2.15. Foreign currency is now expected to be neutral to revenue rather than a tailwind of 0.5%, placing greater weight on the anticipated conversion of BSI bookings and backlog into organic growth and on continued margin execution.

Management, verbatim

In the third quarter, we achieved very significant margin expansion and non-GAAP EPS growth, driven by our focus on cost discipline and execution.

Frank H. Laukien, President and CEO

Bruker’s positive booking trends continued with the fifth consecutive quarter of Bruker Scientific Instruments (BSI) book-to-bill greater than one.

Frank H. Laukien, President and CEO

With BSI organic bookings and backlog both up mid-single digits % year-to-date, we expect revenue growth acceleration, continued margin expansion and double-digit EPS growth in FY27.

Frank H. Laukien, President and CEO

Not in the filing

stated, not guessed
  • Q3-26 GAAP and non-GAAP income tax expense or benefit was not separately presented as a reconciled non-GAAP income tax expense or benefit line item.
  • Q3-26 capital repurchases were not reported.
  • Q3-26 total debt was not reported as a single total-debt figure.
  • Q3-26 gross margin guidance, operating expense guidance, and tax-rate guidance were not provided.
  • Prior-quarter comparisons for reported Q3-26 metrics were not provided.
  • Year-over-year percentage changes for Bruker BIOS, Bruker MID, and Bruker Nano revenue were not printed.
  • Revenue or earnings contribution drivers for Bruker BIOS, Bruker MID, and Bruker Nano were not separately stated.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Q2-26

AlphAI · Earnings readBRKR · Q2-26 · ended June 30, 2026

Q2-26 revenue of $838.5 million, up +5.2% yoy; GAAP diluted loss per share of $(0.41) and non-GAAP diluted EPS of $0.49.

→Mixed quarter

Revenue returned to organic growth and non-GAAP operating income, margin and EPS improved, but GAAP results were affected by $134.9 million of non-cash goodwill impairment charges and US academic demand remained soft.

Revenue
$839M
5.2% y/y
Bruker Scientific Instruments (BSI), Q2-26
$767M
4.7% y/y
Operating margin · non-GAAP
14.1%
EPS · non-GAAP
$0.49
FY26 outlook
$3.54 to $3.57 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, Q2-26GAAP$838.5M–5.2%
Organic revenue growth, Q2-26other2.8%––
Organic revenue growth excluding tariff refunds, Q2-26other3.4%––
Growth from acquisitions, Q2-26other1.5%––
Constant-exchange rate revenue growth, Q2-26other4.3%––
Foreign currency translation impact, Q2-26other0.9%––
GAAP operating loss, Q2-26GAAP−$65.3M––
Non-GAAP operating income, Q2-26non-GAAP$118.5M––
Non-GAAP operating margin, Q2-26non-GAAP14.1%––
GAAP diluted loss per share, Q2-26GAAP$(0.41)––
Non-GAAP diluted EPS, Q2-26non-GAAP$0.49––
Total revenue, first half of 2026GAAP$1.7B–3.9%
Organic revenue growth, first half of 2026other(0.8%)––
Growth from acquisitions, first half of 2026other2.0%––
Constant-exchange rate revenue growth, first half of 2026other1.2%––
Foreign currency translation impact, first half of 2026other2.7%––
GAAP operating loss, first half of 2026GAAP−$55.1M––
Non-GAAP operating income, first half of 2026non-GAAP$202.7M––
Non-GAAP operating margin, first half of 2026non-GAAP12.2%––
GAAP diluted loss per share, first half of 2026GAAP$(0.39)––
Non-GAAP diluted EPS, first half of 2026non-GAAP$0.80––
Non-cash goodwill impairment charges, Q2-26GAAP$134.9M––

Segments

SegmentRevenueq/qy/y
Bruker Scientific Instruments (BSI), Q2-26Organic revenue increased by 2.3%; bookings were up 10% organically year-over-year and book-to-bill was >1.0x.$767.3M–4.7%
Bruker Energy & Supercon Technologies (BEST), Q2-26Organic revenue increased by 8.9%, net of intercompany eliminations.$74.2M–11.9%
Bruker Scientific Instruments (BSI), first half of 2026Revenue decreased by 1.4% organically.$1.5B–3.3%
Bruker Energy & Supercon Technologies (BEST), first half of 2026Organic growth was 6.1%, net of intercompany eliminations.$141M–12.3%

FY26 outlook

  • Revenue$3.54 to $3.57 billion
  • Tax rate27.5%
  • Note3% to 4% year-over-year reported revenue growth
  • NoteOrganic revenue growth of 1% to 2%
  • NoteM&A revenue growth of approximately 1.5%
  • NoteCER revenue growth of 2.5% to 3.5%
  • NoteForeign currency translation revenue tailwind of approximately 0.5% (previously 1.5%)
  • NoteNon-GAAP EPS of $2.10 to $2.15
  • NoteNon-GAAP EPS growth of 15% to 17% year-over-year
  • NoteCurrency headwind of approximately $0.10, or 5%

What drove it

  • Q2-26 BSI bookings were up 10% organically year-over-year, with BSI book-to-bill >1.0x.
  • Bruker cited strong order bookings growth for differentiated products and solutions in semiconductor tools, energy research and biopharma markets.
  • Europe and China aca/gov bookings were up strongly.
  • Q2-26 reported revenue growth included 1.5% growth from acquisitions and a favorable 0.9% foreign currency translation impact.
  • Management cited a focus on cost and profitability and reported non-GAAP operating-margin expansion.

Concerns

  • US academic demand remained soft in Q2.
  • First-half revenue decreased organically by 0.8% year-over-year.
  • Q2-26 GAAP operating loss included non-cash goodwill impairment charges of $134.9 million.
  • FY26 foreign currency translation revenue tailwind is approximately 0.5%, previously 1.5%.
  • FY26 non-GAAP EPS includes a currency headwind of approximately $0.10, or 5%.

What to watch

  • Whether BSI bookings growth and book-to-bill >1.0x translate into sustained revenue growth.
  • The trajectory of US academic demand and the stated gradual market recovery.
  • Execution toward FY26 organic revenue growth of 1% to 2%.
  • Delivery of FY26 non-GAAP EPS of $2.10 to $2.15 at an effective non-GAAP tax rate of 27.5%.
  • The extent of organic margin expansion anticipated by management in 2026 and 2027.

Analysis

Bruker reported Q2-26 revenue of $838.5 million, up 5.2% year-over-year, and returned to organic growth of 2.8%. Organic growth was 3.4% excluding tariff refunds. Reported growth also reflected 1.5% growth from acquisitions and a favorable 0.9% foreign currency translation impact. For the first half, however, organic revenue decreased by 0.8% year-over-year, showing that the Q2 improvement followed a softer first-quarter backdrop.

BSI generated $767.3 million of Q2 revenue, up 4.7% year-over-year, while organic revenue increased 2.3%. The more significant demand indicator was BSI bookings, which increased 10% organically year-over-year, with book-to-bill above 1.0x. BEST grew faster, with revenue of $74.2 million up 11.9% and organic revenue up 8.9%, net of intercompany eliminations. Management identified semiconductor tools, energy research and biopharma as areas of strong order bookings, while US academic demand remained soft.

Profitability improved materially on the non-GAAP basis. Non-GAAP operating income rose to $118.5 million from $72.0 million, and non-GAAP operating margin improved to 14.1% from 9.0%. Non-GAAP diluted EPS increased to $0.49 from $0.32. GAAP operating loss was $(65.3) million and GAAP diluted loss per share was $(0.41), with second-quarter GAAP results including $134.9 million of non-cash goodwill impairment charges.

Bruker updated FY26 guidance for currency and tax only. It expects revenues of $3.54 to $3.57 billion, organic growth of 1% to 2%, and non-GAAP EPS of $2.10 to $2.15. The outlook incorporates an approximately 0.5% foreign currency translation revenue tailwind, previously 1.5%, and a currency headwind of approximately $0.10, or 5%, to non-GAAP EPS. The key reporting priorities are conversion of elevated BSI bookings into revenue, recovery in US academic demand, and continuation of the reported non-GAAP margin expansion.

Management, verbatim

We returned to organic revenue growth in the second quarter and our Scientific Instruments segment achieved 10% organic bookings growth year-over-year.

Frank H. Laukien, President and CEO

Our focus on cost and profitability resulted in solid margin expansion and non-GAAP EPS growth in the quarter.

Frank H. Laukien, President and CEO

In our academic and medical research business, US academic demand remained soft in Q2, while aca/gov bookings in Europe and China were up strongly.

Frank H. Laukien, President and CEO

Not in the filing

stated, not guessed
  • Q2-26 GAAP gross profit, gross margin, net income, cash flow from operations, free cash flow, cash balance, debt balance, dividends and share repurchases were not provided in the supplied filing text.
  • Q2-26 non-GAAP gross profit, non-GAAP gross profit margin, non-GAAP net income, non-GAAP SG&A expense, non-GAAP interest and other income (expense), net, non-GAAP profit before income taxes and non-GAAP income tax rate were not provided in the supplied filing text.
  • FY26 guidance for gross margin and operating expenses was not provided in the supplied filing text.
  • Prior-quarter comparisons for reported metrics were not provided in the supplied filing text.
  • A previous outlook section was not provided, so comparison of actual results with prior guidance cannot be made.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about BRKR earnings dates

When is Bruker's next earnings date?
AlphAI has no date for BRKR yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.